The renin-angiotensin-aldosterone (RAA) system and the endothelin (ET) system entail the most potent vasopressor mechanisms identified to date. Although they were studied in depth in relation to arterial hypertension and cardiovascular diseases, limited information on their interrelationships in causing hypertension and related target organ damage exists. The identification of consensus sequences for jun in the regulatory region of the preproendothelin-1 (ppET-1) gene raised the possibility of its transcriptional regulation by angiotensin II (Ang II). This was confirmed by the finding that stimulation with Ang II of cultured vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) induced expression of the ppET-1 gene and synthesis of ET-1. Endogenously produced ET-1 was found to contribute to the hypertrophic response of cardiomyocytes to Ang II and thereby to cardiac hypertrophy. Furthermore, ET-1 exerts multifaceted effects on the RAA system, such as dose-dependent inhibition of renin synthesis, and stimulation of aldosterone secretion. The finding of abundant specific ET-1 receptors in the adrenocortical zona glomerulosa (ZG) suggested a direct secretagogue effect of ET-1. In rats, ET receptors mediate such an effect, whilst in humans, both ET and ET receptor subtypes intervene in regulating the B A B transcription of the aldosterone synthase gene. In addition, ET-1 stimulates DNA synthesis and proliferation of ZG cells via ET receptors A and, therefore, might play a role in cell turnover of the normal adrenal cortex and in the onset of adrenal tumours. Studies on the in vivo interactions between ETs and the RAA system have given conflicting results, insofar as some suggested a participation of ET-1 in the pressor and cellular effects of exogenously administered Ang II, whereas others did not in the transgenic TGR(Ren 2m)27 rats and in the two-kidney, one clip.
Introduction
with emphasis on the role of endothelin-1 (ET-1) in the regulation of the RAAS and on in vivo studies supporting The renin-angiotensin-aldosterone system (RAAS) and a co-operation of both systems in the regulation of the endothelin (ET) system are two of the most potent cardiovascular and adrenocortical function. vasopressor mechanisms identified to date (for a review, see [1] [2] [3] ). Therefore, it is not surprising that they have been investigated extensively in relation to arterial hy-2. Potential sites of interaction pertension and related cardiovascular disease. However, despite this vast body of investigations, only limited Several potential sites of interaction between the RAAS information exists on their reciprocal relationships. Thus, and ET system, spanning from the molecular level to the in in this paper, we shall review available knowledge on the vivo hormonal and haemodynamic regulation, can be interactions between these two important pressor systems, envisaged. It has been hypothesised that Ang II, the active peptide of the RAAS, affects the synthesis of ET-1, which, in turn, can influence the RAAS by acting at different steps ( Fig. 1 ). In keeping with this hypothesis, consensus sequences for jun were identified in the regulatory regions of the preproendothelin-1 (ppET-1) gene [4] , suggesting the possibility of transcriptional regulation of this gene by factors acting through the G-protein-phospholipase Cprotein kinase C pathway ( Fig. 2 ) [5, 6] . Of interest, an additional site of interaction between the RAAS and ET system has recently been identified at the level of ET-1 biosynthesis. Although the predominant ET biosynthetic pathway involves the specific cleavage of pro(big)ET-1 by ECE-1, the possibility that bigETs are also cleaved by human chymase, the enzyme responsible for most of the conversion of Ang I to Ang II in the myocardium [7] (Fig. 2) , has been suggested, based on the observation that the rat chymase was shown to cleave 31 32 bigETs at the Try -Gly bond [8], leading to novel 1-31 endothelin isopeptides, ETs(1-31). The latter were shown in vitro to exert a less potent but slower-developing and a longer-lasting contraction than ETs(1-21) in porcine coronary artery and rat aorta. Interestingly, at variance with ET-1, this vasoconstriction of ETs(1-31) was also found to be inhibited by either the ET antagonist BQ-485 or the A ET antagonist BQ-788 and, therefore, these novel pep-B tides might act in a different manner from endothelins [9], possibly through different receptors. ET-1 was found to exert multifaceted effects on the RAAS, such as dose-dependently inhibiting renin production, directly stimulating aldosterone production from at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from might be relevant for the regulation of both function and hypertrophy, the data suggesting an effect of the peptide on cell turnover of the adrenal cortex under physiological and ET-1 transcription raised the possibility that ET-1 might pathophysiological conditions. also intervene in hypertension-related left ventricular hypertrophy and remodelling. This contention is supported by the observation that endogenously produced ET-1 con-3. Effect of the RAAS on endothelin-1 tributed to the hypertrophic response of cardiomyocytes to both Ang II and ET-3 [17] . Thus, ET-1 antagonism may The identification of consensus sequences for regulatory offer an additional weapon for therapeutic interventions elements in the regulatory region of both the ppET-1 gene aimed at preventing cardiovascular damage. The demon- (Fig. 3) and the endothelin converting enzyme 1 (ECE-1) stration that long-term treatment with ET antagonists not gene suggested the possibility that both of these key-genes only greatly improved the survival of rats with chronic involved in ET-1 biosynthesis are regulated by the same heart failure, but also prevented ventricular remodelling, factors. The hypothesis that Ang II can turn on the i.e., the increase in left ventricular mass and cavity transcription of the ppET-1 gene is supported by the in enlargement [19] , as well as the increase in collagen vitro findings that human and porcine cultured vascular density [20] , strongly supports this view. smooth muscle cells (VSMCs) [12] [13] [14] and endothelial cells (ECs) [15, 16] can express the preproET-1 gene and synthesise immunoreactive (ir) ET-1 upon stimulation with Ang II. Evidence indicates that Ang II turns on the 4. Effect of ET-1 on the RAAS transcription of the ppET-1 gene by acting via AT-1 receptors linked to activation of transcription via activator Besides its potent haemodynamic effects, the intravenprotein-1 / kinase C-mediated mechanisms [14, 15, 17, 18] .
ous infusion of ET-1 in animals and humans was found to However, the possibility of complex cross-talk between deeply affect the RAAS. Renin secretion from juxtagseveral signalling pathways that can be activated by a lomerular cells was generally decreased by ET-1 both in number of humoral factors, such as insulin, catecholvitro and in vivo, as shown by seven out of eight available amines, components of the clotting / fibrinolysis cascade, studies [21] [22] [23] [24] [25] [26] [27] [28] . Collectively, available evidence is conand cytokines, as depicted in situations, for instance, in pregnancy-induced hypertenure, malignant and severe hypertension, endotoxaemia and sion, a vasospastic and volume-reduced disorder where in transplant recipients. endothelial cell damage is suspected to play an important role. Compared to normal pregnancy, pregnancy-induced hypertension was found to be associated with a two-fold 5. In vivo interactions of ET-1 and the RAAS increase in plasma irET-1 levels, which may be responsible for the inappropriately low plasma renin activity in
To investigate whether the aforementioned in vitro relation to the reduced plasma volume [28] .
interactions between ET-1 and RAAS have an in vivo The observation that, despite this inhibitory effect on counterpart, a number of studies have been carried out. renin, ET-1 was found to markedly stimulate aldosterone Among the original observations stimulating these insecretion both in animals and in humans, suggested a direct vestigations was the report that subthreshold concentraeffect of the peptide on the adrenal cortex (for review, see tions of ET-1, i.e., lower than the concentration range Ref. [10] ). This contention was confirmed by findings of (30-300 pM) needed to elicit a contractile response, were abundant specific ET and ET receptors in the human and able to potentiate the vasoconstrictor response to well A B
animal adrenal ZG [29] [30] [31] as well as by in vitro studies known vasoconstrictors, such as serotonin and histamine [32] [33] [34] [35] , which clearly indicated that, in rats, the ET [43] . In male HanRen2 / Edin rats derived from crossing B receptor subtype mediates the direct secretagogue effect of the homozygote transgenic TGR(mREN-2)27 with Edin-ET-1 on aldosterone [36] . At variance with findings in rats, burgh Sprague-Dawley rats, which show a 73.5% inciavailable data in humans indicate that both the ET and dence of the malignant phase of hypertension, an increased A ET receptors are involved [37] in the transcriptional ET-1 mRNA content was found in the kidney in the B regulation of the aldosterone synthase gene, both in animals that developed malignant hypertension [44] . Noneadrenocortical carcinoma and in normal human adrenal theless, no effect of the mixed ET / ET endothelin A B cells [38] . Similar results were recently obtained by antagonist bosentan [45] was seen on blood pressure. At another group working independently [39] . Of interest, in variance with these findings, bosentan pre-treatment was vitro in dispersed normal human adrenocortical ZG cells, capable of blunting the increase in blood pressure, the fall as well as in Conn's adenoma cells, ET-1 was found to be in cardiac output, and the decrease in arterial conductance equipotent to Ang II [38] , the most important physiological evoked by an infusion of Ang II, both in WKY and in SHR secretagogue of aldosterone identified so far. Further rats [46] . This blunting was more pronounced in SHR rats, experiments from our group provided unequivocal evieven thought it was seen in both strains, but it was evident dence that, in the rat adrenal ZG, by acting via ET at the lower (2-10 ng / kg / min) but not at the higher (.30
A receptors, ET-1 stimulates both DNA synthesis and cell ng / kg / min) doses of Ang II, thereby suggesting the proliferation [40] . Since these latter effects were dosepossibility of an ET-1 component only in the initial pressor dependently blunted by the protein-kinase C inhibitor effect of Ang II. In partial agreement with this contention, Ro31-8220 and by the tyrosine-kinase inhibitor tyrphostina five-day-infusion of Ang II (0.7 mg / kg / day) to Sprague-23, they are likely to involve activation of both of these Dawley rats was found to markedly enhance immunokinase signalling pathways, but not the protein-kinase A, staining for ET-1 in VSMCs; furthermore, administration cyclooxygenase and lipoxygenase signalling pathways of the ET -selective antagonist PD 155080 abolished the A [40] . Based on these findings, we hypothesised that ET-1 rise in blood pressure, as did the Ang II AT-1 receptor may enhance the growth of the entire adrenal gland by antagonist losartan [47] . In 1997, a number of studies acting on the 'cambium' layer of cells endowed with ET carried out in Dr. Luscher's laboratory suggested that ET-1 A receptors, which are mainly located in the ZG. [41] . could play an important role in the structural changes However, in recent in vivo experiments in rats, it was induced by Ang II infusion. Two weeks of Ang II infusion found that the administration of the ET -specific antago-(200 ng / kg / min) increased media thickness, the media- for four weeks did not affect adrenal gland weight, casting and cerebral arterioles, and nearly doubled the content of doubts on the relevance of ET-1 in the maintenance of the ET-1 in the mesenteric tissue, through mechanisms most volume of the entire gland in this species (for review, see likely involving the ET receptor, inasmuch as the specific A Ref.
[42]). antagonist LU135252 was able to prevent both the deThus, collectively, these data indicate that ET-1 potently velopment of medial hypertrophy and increased peptide stimulates aldosterone secretion and suggest that it may content in both types of vessels [48] . It was also shown affect adrenocortical growth through a direct action on that a two-week-infusion of a similar dose of Ang II led to specific receptors, albeit with differences among species.
enhanced vascular endothelin converting enzyme activity These effects of ET-1 are potentially relevant in several and renal ET-1 content in WKY rats [49] and that conditions where endothelial damage, hypertension and LU135252 lowered the Ang II-induced pressure increase hyperaldosteronism coexist, such as congestive heart failand improved endothelium-dependent relaxation [50] . The hypothesis that ET-1 might play a role not only in the closely paralleled those of their systolic blood pressure, haemodynamic effects of Ang II but also in the mechathereby suggesting a role for ET-1 in this form of reninnisms of related cardiovascular damage, is further supdependent hypertension [55] , in agreement with previous ported by three sets of observations. First, bosentan reports [56] . However, in contrast with this contention and entirely prevented the development of hypertension, the in keeping with the aforementioned results in the reduction in renal blood flow and the marked increase in HanRen2 / Edin rats cross [44] , bosentan did not have albuminuria and heart weight induced by a ten-day infueither a blood-pressure-lowering effect or any effectiveness sion of Ang II (200 ng / kg / min) [51] . Second, in a canine in preventing left ventricular and vascular hypertrophy in model of Page (kidney wrapping) hypertension, bosentan male heterozygote TGR(mREN-2)27 rats. These findings was found to exert a hypotensive effect in addition to that were in sharp contrast with the efficacy of the angiotensin of the AT-1 receptor antagonist losartan [52] . This additive II AT-1 receptor antagonist irbesartan in lowering blood hypotensive effect was found also in a study on rats with pressure and preventing left ventricular and arteriolar renin-dependent hypertension [53] .
hypertrophy in the same model. Thus, it would appear that An animal model that lends itself to the investigation of in this form of severe hypertension, due to overexpression the interactions between the RAA and ET systems in vivo of a renin gene, ET-1 does not play any major role. This is the TGR(mREN-2)27 rat. In this model, the introduction conclusion is only partially supported by findings in twointo the rat genome of the mouse Ren-2 gene, encoding for kidney one-clip hypertension rats. In this animal model of renin, causes severe hypertension, which is associated with renovascular hypertension, the orally active endothelin overexpression of the transgene in several tissues, parantagonist Ro-00203, whilst having no significant effect on ticularly in the adrenal cortex and the vessel wall, with renin secretion and renin gene expression, attenuated the ensuing enhanced endogenous production of Ang II in rise in blood pressure elicited by clipping one renal artery, tissues and low plasma renin activity [54] . A marked although it did not abolish it [57] . sexual dimorphism of blood pressure changes exists in this
The reasons why ET-1 may take part in hypertension model. In fact, while males develop severe hypertension, induced by exogenously administered Ang II, but not in which is fulminant in homozygotes and somehow less the models with an enhanced endogenous production of severe in heterozygotes, the female TGR(mREN-2)27 rats Ang II, are unclear at present. They might depend upon the have a milder form of hypertension, which in different tissue levels attained by Ang II and / or the heterozygotes peaks at approximately ten weeks of age and different gradients between the bloodstream, endothelium then spontaneously returns to normal values by 35 weeks and VSMCs of the blood vessels' tunica media, in these of age. Thus, these heterozygote female rats can be two situations. In fact, it is well documented that, in maintained without any antihypertensive treatment. Of heterozygote TGR(mREN-2)27 rats, a high tissue expresinterest, we recently reported that, in these female animals, sion of Ang II occurs together with low plasma Ang II, the aortic responsiveness to ET-1 followed changes that whilst in the models with exogenous Ang II administra- Fig. 4 . Endothelin-1-dependency of hypertension in different experimental animal models (see Ref. [58] for review) on an arbitrary scale. Regardless of the initial ET-1 dependency, the pathogenic role of the ET system is deemed to get more and more important once endothelial and target organ damage supervene.
at Pennsylvania State University on February 23, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from tion, the peptide concentrations are likely to be high in 260 mmHg and, thus, almost normalised blood pressure. plasma and lower in tissues.
Thus, the combined ET / RAAS inhibition may provide an In contrast with the controversial data on the ininteresting synergistic potential in terms of blood pressure volvement of ET-1 in renin-dependent forms of hypertenreduction. Of further interest, this synergism was found sion, rather concordant data on the role of the peptide in also in patients with class III New York Heart Association mineralocorticoid-dependent forms of hypertension exist (NYHA) congestive heart failure, who were haemodynam-(for a review, see Ref. [58] ). Increased levels of irET-1 ically stable on ACE inhibitors and diuretics, in whom the were found both in plasma and in the arterial wall of rats mixed ET / ET receptor antagonist bosentan elicited a A B
with deoxycorticosterone acetate (DOCA)-salt-induced clear-cut decrease in systemic and pulmonary vascular hypertension [59] [60] [61] . Elegant in situ hybridisation studies resistance along with an increase in the cardiac index [67] . by Day et al. [62] showed enhanced expression of the ppET-1 gene in the vessel wall in the same model. Treatment with bosentan was quite effective in preventing 7. Conclusions and perspectives vascular hypertrophy in this model. This finding lent further support to the contention of a direct involvement of
The identification of ET-1 by Yanagisawa et al.
[68] one ET-1 in target organ damage in this low-renin form of decade ago has added a novel important player to the hypertension [63] . The contention that ET-1 plays an 'arena' of potential mechanisms causing arterial hypertenimportant role in salt-dependent forms of hypertension is sion and related cardiovascular disease. Over the years, it further supported by the findings of Barton et al. [64] , who has been increasingly appreciated that any newly discovreported that the ET -specific antagonist LU135252 was ered agent cannot be investigated singularly, but rather A able to partially prevent the development of hypertension should be assessed in the context of all the other known and the structural and functional alterations caused by mechanisms. There are several interactions between the chronic salt administration in Dahl salt-sensitive rats. A RAAS and the endothelin system, which may have relrole for ET-1 in cardiovascular damage of salt-sensitive evant effects on blood pressure and on hypertensionhypertension is suggested also by data obtained in humans related complications. Experimental research has started to [65] . unravel these interactions, and pilot clinical trials gave Fig. 4 summarises available data on the participation of promising results, but the question of whether or not they endothelin in experimental models of hypertension. It must are also relevant in humans in the clinical setting and have be pointed out, however, that regardless of the initial ET-1 therapeutic implications needs to be investigated further. dependency of hypertension, the pathogenic role of the ET system is deemed to get more and more important as endothelial and target organ damage supervene.
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